If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
IPO today
Upcoming IPO
Mallard Acquisition (MACUU)
MingZhu Logistics Holdings (YGMZ)
Good Works Acquisition (GWACU)
Bull Horn Holdings (BHSEU)
Decarbonization Plus Acquistion (DCRBU)
Horizon Acquisition II (HZON.U)
Helix Acquisition (HLXA)
Datto Holding Corp. (MSP)
McAfee Corp. (MCFE)
Guild Holdings Company (GHLD)
Abcam plc (ABCM)
Foghorn Therapeutics Inc. (FHTX)
Gatos Silver, Inc. (GATO)
Priced IPO
Opthea Limited (OPT)
Eargo, Inc. (EAR)
Aligos Therapeutics, Inc (ALGS)
Praxis Precision Medicines, Inc. (PRAX)
Tarsus Pharmaceuticals, Inc. (TARS)
Array Technologies, Inc. (ARRY)
MINISO Group Holding Limited (MNSO)
Codiak BioSciences, Inc. (CDAK)
Intrusion Securties Inc. (INTZ)
iHuman Inc. (IH)
Shattuck Labs, Inc. (STTK)
Kronos Bio, Inc. (KRON)
Spruce Biosciences, Inc. (SPRB)
Aziyo Biologics, Inc. (AZYO)
fuboTV Inc. (FUBO)
Presidio Property Trust (SQFT)
Academy Sports and Outdoors, Inc. (ASO)
Immunome Inc. (IMNM)
C4 Therapeutics, Inc. (CCCC)
Oncorus, Inc (ONCR)
More companies

PMV Pharmaceuticals, Inc (PMVP)

Sector - Healthcare

Price chart

Company News

IPO Profile

About company

They are a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations. They believe that they have designed their lead product candidate, PC14586, to potently and selectively correct p53 misfolding caused by a specific p53 mutation, Y220C, while sparing wild-type p53. The Y220C mutation is associated with 1.0-1.5% of all cancers, including breast, non-small cell lung cancer, or NSCLC, colorectal, pancreatic and ovarian cancers. While they are in the early stages of discovery and development of their product candidates and their novel approach is unproven, they are initially pursuing a tumor-agnostic development strategy and submitted their investigational new drug application, or IND, for PC14586 on August 5, 2020 and plan to start a Phase 1/2 clinical trial in the second half of 2020. Their strategy is to seek approval under an accelerated pathway, and they believe their Phase 1/2 clinical trial has the potential to serve as a pivotal study. They cannot guarantee that the U.S. Food and Drug Administration, or FDA, will agree with this strategy of utilizing the Phase 1/2 clinical trial as a pivotal study, which could require them to conduct additional clinical trials prior to seeking FDA approval.
David H. Mack Winston Kung
Employees Founded
39 2013


Address: 8 Clarke Drive, Suite 3 Cranbury, NJ 08512

Telephone: (609) 642-6670

Web page:

IPO information

Expected Date 9/25/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
Share prices ($)

Financial Data (last reporting year)

Market Cap (MM) $655.86
Revenues (MM) $0
Net Income (Loss) (MM) $-40.6


What do you think will happen with the PMVP share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
Shares Initial (MM) 7.35
Shares Revised (MM) 11.8
Expected offer amount (MM) $124.95
Realized offer amount(MM) $212.4
Goldman Sachs/ BofA Securities/ Cowen/ Evercore ISI

Sector: Healthcare

Tweets about $PMVP

Tweets volume:

RT volume:


Google Trends Stats